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Patients with recurrent or refractory head and neck squamous cell carcinoma received cisplatin/epinephrine injectable gel or
placebo gel injected directly into the clinically dominant tumour. The double-blind phase III trial comprised of up to 6 weekly
treatments over 8 weeks, 4 weekly evaluation visits, and then monthly follow-up; open-label dosing began as needed after
three blinded treatments. Tumour response was deﬁned as complete (100% regression) or partial (50–99% regression)
sustained for 528 day, and patient beneﬁt as attainment of palliative or preventive goals prospectively selected by
investigators and patients. With cisplatin/epinephrine gel, 25% (14 out of 57) of tumours responded (16% complete
regression, 9% partial regression), vs 3% (one out of 35, complete regression) with placebo (P=0.007). Patient beneﬁt was
positively associated with target tumour response in the blinded period among cisplatin/epinephrine gel recipients (P=0.024):
43% (six out of 14) of responders beneﬁted, vs 12% (ﬁve out of 43) of non-responders. The most frequent adverse event
was pain during injection and the next most frequent was local cytotoxic effects consistent with the gel’s mode of action.
Systemic adverse events typical of intravenous cisplatin were uncommon. Intratumoural therapy with cisplatin/epinephrine gel
provided safe, well-tolerated, effective palliative treatment for patients with locally advanced head and neck squamous cell
carcinoma, who lack other satisfactory treatment options.
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recurrence
Despite aggressive early therapy, resistant head and neck squa-
mouse-cell cancers (HNSCC) often recur, accompanied by
distressing symptoms (Khuri et al, 2000). Options for local control
in relapse are limited: prior extensive surgery and radiation therapy
raise the risk of unacceptable complications with additional similar
interventions. The intensiﬁcation chemotherapy regimens required
for effective local-regional control are highly toxic (Pignon et al,
2000), particularly in debilitated late-stage patients who typically
develop recurrent head and neck cancer (Havlin et al, 1989;
Robbins et al, 1994).
Intratumoural chemotherapy has been investigated for managing
treatment-resistant tumours by exposing cancers to more cytotoxic
agent than feasible with systemic dosing, while minimizing systemic
exposure and adverse effects. Cisplatin/epinephrine injectable gel
(CDDP/epi gel or IntraDose
1; Matrix
1 Pharmaceutical, Inc,
Fremont, CA, USA (Drug licensed to Chiron Corporation, Emery-
ville, CA, USA)) contains cisplatin and epinephrine in a
biocompatible and biodegradable aqueous gel matrix of puriﬁed
bovine collagen. The gel is injected directly into tumours under
visual guidance or aided by cross-sectional imaging techniques.
The gel’s viscosity and epinephrine-induced vasoconstriction delay
cisplatin clearance from tumours, prolonging exposure of malignant
cells and sparing distant sensitive normal tissues (Mok et al, 2001).
Intratumoural platinum concentrations 10 to 100 times those after
systemic cisplatin treatment have been recorded for 1 to 3 days
(Yu et al, 1995). In clinical experience with CDDP/epi gel in solid
tumours, adverse effects typical of systemically administered cispla-
tin were rare and mild (Burris et al, 1998). Efﬁcacy and clinical
beneﬁt of the drug for local tumour control has been demonstrated
in phase II open-label trials for a variety of solid tumours including
cutaneous and soft tissue metastases of malignant melanoma (Oratz
et al, 2002), recurrent breast cancer (Roshon, 2001), oesophageal
(Harbord et al, 2002), and gastric cancer (Monga et al, 1998), and
primary and secondary malignant liver tumours (Leung et al,
2001; Thuluvath et al, 2001; Vogl et al, 2002).
The present study was a randomised, double-blind, placebo-
controlled investigation of the safety and efﬁcacy of CDDP/epi
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mous cell carcinoma. We hypothesized that regression of the
clinically dominant tumour consequent to local treatment with
CDDP/epi gel would improve patient well-being by relieving or
preventing the most life-impacting symptom. To explore this
hypothesis, we evaluated the response of the clinically dominant
tumour; Patient beneﬁt, an endpoint based on the attainment of
prospectively selected treatment goals; and the relationship between
these two variables. The protocol and consent forms were approved
by the Institutional Review Board at each study site before study
initiation, all patients signed a written informed consent before
enrollment, and the study was conducted in accordance with Good
Clinical Practices.
MATERIALS AND METHODS
Eligibility and study entry
Entrants were required to have histologically conﬁrmed, recurrent
or refractory, primary or metastatic head and neck squamous cell
carcinomas. Previous treatment with 5one course of therapy
was obligatory, but patients must have recovered fully from any
adverse effects of prior treatment. Patients who had a change in
clinical status but required no intravenous chemotherapy were
allowed to participate in the study. It was mandated that patients
have tumours that were problematic and requiring intervention
for the local problem. Tumours considered for treatment had to
be 0.5 to 42c m
3 in volume, readily measurable, accessible for
direct intratumoural injection, and pose no immediate risk of
haemorrhage or embolisation. Karnofsky Performance Status
(KPS) of 540, later amended to 560, and an expected survival
of at least 6 months were required.
Patients were excluded if they had New York Heart Association
Class III or IV cardiovascular symptoms or a history of cardiac
arrhythmia that might increase their risk of arrhythmia upon
dosing; a tumour of the head or neck other than squamous cell
carcinoma; or a history of clinically signiﬁcant extracranial carotid
vascular disease. Those hypersensitive to cisplatin, bovine collagen,
epinephrine, or sulﬁtes were excluded. Fibrotic or infected tumours
were excluded from study treatment, as were tumours involving a
major artery or visceral organ, directly involving or threatening to
invade the carotid artery, or close to a major extracranial vessel.
Use of non-study cancer therapy or investigational agents was
prohibited within 28 days before and throughout the trial. Concur-
rent use of drugs that interact with cisplatin was prohibited.
Patients with no local tumour beneﬁt could continue stable main-
tenance doses of hormonal therapy and radiation therapy to
distant, non-target metastases that developed during the study.
Bupivacaine HCl, cytotoxic or immunomodulating agents, and
corticosteroids were prohibited during the trial (except stable ster-
oid doses for chronic disease, asthma, or anti-emesis). Local or
topical anaesthetic agents not containing epinephrine or adrenaline
were permitted.
Patient assignment and treatment
Investigators identiﬁed a target tumour that met the entry criteria
and was the most symptomatically troublesome or threatening
(e.g., to obstruct airway), and selected a palliative or preventive treat-
ment goal for this tumour (other tumours could be treated but were
not associated with the primary goal). Patients also selected a pallia-
tive goal. According to a stratiﬁed randomisation scheme (using a
computerised list maintained by the sponsor), investigators assigned
patients in a 2:1 ratio to treatment with CDDP/epi gel or placebo gel,
within stratum I (target tumour volume 55c m
3) or stratum II
(target tumour volume 45 but 420 cm
3). Cisplatin/epinephrine
gel 1 ml contained cisplatin 4 mg, epinephrine 0.1 mg, puriﬁed
bovine atelopeptide collagen matrix 20 mg, and excipients; placebo
gel 1 ml contained puriﬁed bovine atelopeptide collagen matrix
20 mg and saline 0.9%. Doses were injected intratumourally at
0.25 ml cm
73 of treated tumour volume. Volume was estimated as
length6width6height60.5. Any portion of the 10-ml maximal
permitted dose remaining after target tumour injection could be used
to treat other qualifying tumours.
Before starting treatment, the investigator developed a pain
management programme including, as needed, topical and local
anaesthetics, local-regional nerve blocks, and systemic agents.
Patients were treated as outpatients or during a brief hospital stay.
Using a 22- to 30-gauge needle Luer-lock syringe, with a fanning or
grid technique, the physician injected the gel in tracks about
1.0 cm apart throughout the entire tumour and a 1- to 2-cm zone
surrounding the tumour margin. Extreme care was used to avoid
injecting gel into a blood vessel. Investigators were instructed to
inject the total gel volume slowly, in 2.5-ml increments, waiting
about 5 min between injections, and checking pulse and blood
pressure immediately and about 5 min after each incremental
administration. Wound care measures included conservative
wound management, early use of antibiotics for suspected infec-
tion, and delays in therapy if necessary.
Up to 6 weekly treatments were administered in an 8-week period
(blinded treatment phase), followed by evaluations weekly for 4
weeks and then monthly for 5 months until study discontinuation
or disease progression. If after three treatments the tumour(s) had
progressed or only partially responded, patients could enter an
open-label phase to receive active drug. Investigators, patients, and
sponsor remained blinded to patients’ initial treatment assignments
until the last patient enrolled in the study completed 6 months of
follow-up. Blinding was ensured by packaging CDDP/epi gel in iden-
tical cartons. At the study site, test drug was prepared by a pharmacist
then given to the physician for administration.
Evaluations
Volume of tumours to receive study treatment was measured at
each visit. Response of the target and other treated tumours was
based on maximal decrease from baseline in tumour volume
during the blinded phase. Tumour response was classiﬁed as
complete response (CR, 100% reduction in volume lasting 528
days); partial response (PR, 50–99% reduction in volume lasting
528 days); stable disease (450 reduction in or 425% increase
in detectable, evaluable malignant disease; i.e., no signiﬁcant
measurable change); or progressive disease (425% increase in
detectable, evaluable malignant disease).
Rate of patient beneﬁt was assessed based on attainment of
prospectively chosen primary treatment goals deﬁned in a new,
validated instrument for measuring beneﬁt associated with treating
local tumours, the Treatment Goals Questionnaire
# (Werner et al,
2000; Mackowiak et al, 2001). Investigators selected an improvable
primary treatment goal for the target tumour from eight palliative
options (wound care; pain control; ability to see, hear, or smell;
physical appearance; obstructive symptoms; and mobility) or three
preventive options (invasion of vital structures and/or blood
vessels, obstruction, or subcutaneous tumours breaking through
the skin). Patients identiﬁed an improvable primary treatment goal
for the target tumour from the eight palliative options. Attainment
of palliative treatment goals was evaluated at screening, week 4,
end of follow-up, and the last study visit, and attainment of
preventive treatment goals at each treatment and follow-up visit.
Patient beneﬁt was achieved only if both patient and physician said
the primary treatment goal was attained or one said the goal was
attained and the other said that tumour-related signs and symp-
toms relevant to the goal did not worsen.
The active and placebo gels were also compared during the
blinded phase for rate of response of all tumours treated; duration
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ted; time to progression of the target tumour and all tumours
treated; and quality of life, as measured by the FACT-H&N (Cella,
1993) administered at weeks 1 and 4 and the end of follow-up.
Treated tumour sites were examined at each visit using a four-
point scale (none, mild, moderate, severe) to assess symptoms of
erosion, erythema, eschar, necrosis, swelling, and ulceration. Safety
evaluations at each visit also included physical examination; blood
pressure and pulse (pre- and post-treatment for treatment visits);
laboratory evaluations (differential blood cell counts; haemoglobin
and haematocrit levels; serum chemistries; serum pregnancy test, if
appropriate, at screening); change in Karnofsky Performance Status
(KPS); and adverse events (immediate injection effects, sustained
local reactions, and systemic/other local reactions at a gel-treated
site). Toxicity grading was based on NCCOG/NCI Toxicity Criteria
(NCCOG/NCI, 1991).
Statistical considerations
Planned enrollment was 90 patients (60 active-gel and 30 placebo-
gel group recipients), the number required to provide a power of
50.80 to detect a difference in response rates conditional on target
tumour volume, using a two-tailed a level of 0.05 (Mun ˜oz and
Rosner, 1984). Primary efﬁcacy analyses for the blinded treatment
phase were comparison of the co-primary endpoints of target
tumour response rates and patient beneﬁt rates across treatment
groups using the Cochran-Mantel-Haenszel (CMH) exact test for
the overall analyses and the Fisher’s exact test for analyses by stra-
tum. Because co-primary endpoints were used, no adjustment for
multiplicity was required. The association of target tumour
response with patient beneﬁt was also examined by the CMH exact
test. Secondary analyses included change in FACT-H&N score and
KPS, time to and duration of target tumour response, effect of
covariates on target tumour response by logistic regression testing,
and response of all treated tumours.
RESULTS
Patient disposition
Twenty-seven investigators enrolled patients at 28 centres in
Europe and Israel, from June 1995 to March 2000. Patients
included those who had received previous treatment with one or
more modalities, had failed previous chemotherapy, were not
candidates for further therapy, or refused therapy. Ninety-two
patients (57 active, 35 placebo) were enrolled in the double-blind
phase: 48 in stratum I (31 active, 17 placebo) and 44 in stratum
II (26 active, 18 placebo). One hundred and eleven tumours were
treated. In the blinded phase, of the 57 patients assigned to CDDP/
epi gel, 25 (44%) completed the planned six treatments and 32
(56%) did not, including 3 (5%) who had an early CR, 3 (5%)
whose systemic disease progressed, 15 (26%) whose target tumour
progressed, 5 (9%) who had unacceptable adverse events, and 6
(11%) who withdrew for other reasons. Among the 35 patients
assigned to placebo, 6 (17%) completed six treatments and 29
(83%) did not, including four (11%) whose systemic disease
progressed, 18 (51%) whose target tumour progressed, and seven
(20%) for other reasons (there were no unacceptable adverse
events). Of the 29 placebo gel recipients who withdrew from treat-
ment during the blinded phase, 24 (12 in each stratum) elected to
cross over to the open-label phase to receive active drug.
Demographics and baseline disease characteristics
The treatment groups were well matched for all demographic and
baseline disease characteristics (Table 1). Baseline KPS was 480 in
53 patients (58%) and 470 in 13 (14%), indicating moderate
function in most patients. One tumour was treated in 90% (83
out of 92) of patients at the ﬁrst treatment visit; the greatest
number of tumours treated in one patient was ﬁve. Patients had
long-standing disease and were heavily pre-treated: 59% had a neck
dissection; 66% had tracheotomy, glossectomy, and/or laryngect-
omy or laryngo-pharyngectomy; and 19% had received two or
more cycles of chemotherapy. Most target tumours were in the
neck and oral cavity, and 90% of them were in a previously irra-
diated ﬁeld.
Target tumour response
During the blinded phase, CR or PR was achieved in 14 patients
(25%, Table 2) treated with CDDP/epi gel; one placebo recipient
had a CR (P=0.007, exact CMH). Duration of response after active
gel therapy was a median of 64 days (stratum I, 61 days; stratum II,
228 days). Twelve of the 14 target tumours that responded to the
active gel were still in local remission when the patients left the
study. Median maximal tumour shrinkage in the ﬁve active gel
recipients with PR was 94% (range, 60–99%). Among responders,
the target tumour was in the oral cavity in 10, the neck in two and
the face in two. Stratum I target tumours responded more often
(32%) than stratum II target tumours (15%). The response rate
was higher in patients who had no prior systemic chemotherapy
(32%) than in those who did (13%), and lower in those who
had prior platinum-based chemotherapy (11%) than in those
who did not (32%), but these differences were not signiﬁcant
(P=0.086 and P=0.19, respectively, logistic regression analysis).
Response of the target tumour to CDDP/epi gel became more
likely as the number of treatments increased: 42% (10 out of 24)
of target tumours responded with ﬁve–six treatments, 12% (three
out of 25) with three–four treatments, and 13% (one out of eight)
with one–two treatments.
Among 24 patients who failed placebo treatment and then
received CDDP/epi gel, seven (21%) responded after a median of
four (range, three–ﬁve) active gel treatments. Of patients who
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Table 1 Demographic data and baseline medical status
CDDP/epi Gel Placebo Gel
Variable (n=57) (n=35)
Age: mean (range) 60 (37–82) 62 43–84)
Sex: number and % male 45 79% 30 86%
KPS: median (range) 80 (50–100) 80 (40–100)
FACT-H&N: median (range) 105 (65–136) 103 (62–132)
Total treated tumours: number and %
1–2 56 98% 34 98%
53 1 2% 1 2%
Target tumour location: number and %
Cervical 21 37% 20 57%
Facial 6 11% 6 17%
Oral 24 42% 8 23%
Other 6 10% 1 3%
Target tumour classiﬁcation: number and %
Primary 31 54% 13 37%
Metastatic 26 46% 22 63%
Target tumour volume (cm
3): median (range) 4.9 (0.75–20) 5.3 (0.50–20)
Total treated tumour volume (cm
3), ﬁrst
treatment visit: median (range) 5.3 0.75–20 6.0 0.75–67
Time from diagnosis of primary disease to
ﬁrst treatment (mo): median (range) 17 (3–386) 13 (4–88)
Prior cancer therapy: number and %
Surgery 47 82% 27 77%
Radiation 48 84% 31 88%
Chemotherapy 23 40% 20 57%
Target tumours in previously irradiated
ﬁeld: number and % 49 86% 34 97%
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out of 81 (26%) had target tumour responses (12 CR, 9 PR), with
15 out of 43 (35%) of the responders in stratum I and six out of
38 (16%) in stratum II.
Time to target tumour response to CDDP/epi gel in the blinded
phase was a median of 53 days (range, 10–162); however, in many
patients tissue conditions and tumour location delayed detection of
response. Response to CDDP/epi gel occurred after a median of 4.5
treatments (range, two–six). Mean time to target tumour progres-
sion was 128 days (range, ﬁve–564) in the active group and 44
days (range, six–210+) in the placebo group.
Patient beneﬁt
Physicians most frequently selected wound care (25%) and pain
control (24%) as primary treatment goals, followed by obstructive
symptoms (22%), physical appearance (4%), and ability to see
(1%). More than half of the patients chose either pain control
(34%) or wound care (27%) as their primary treatment goal,
followed by improvement in obstructive symptoms (24%) and in
physical appearance (4%).
In the blinded period, 19% (11 out of 57) of CDDP/epi gel treated
patients (stratum I, 23%; stratum II, 15%) achieved patient beneﬁt vs
9% (three out of 35) of placebo recipients (stratum I, 12%;stratum II,
6%). Although these differences were not signiﬁcant (overall P=0.24,
CMH test; both P50.46, Fisher’s exact test, for strata), active gel reci-
pients were 1.9 to 2.5 times more likely toachieve Patient Beneﬁt than
placebo-treated patients. Among beneﬁters, 64% (nine out of 14)
attained their own palliative goal, 57% (eight out of 14) attained
the investigator-speciﬁed palliative goal, and 29% (four out of 14)
attained the investigator-speciﬁed preventive goal.
Patient beneﬁt was positively and signiﬁcantly (P=0.024, CMH
test) associated with target tumour response in the blinded period
among CDDP/epi gel recipients: 43% (six out of 14) of target
tumour-responders had patient beneﬁt, whereas only 12% (ﬁve
out of 43) of non-responders beneﬁted. Most of this difference
was in stratum I, in which 50% (ﬁve out of 10) of responders bene-
ﬁted vs 10% (two out of 21) of non-responders. In seven patients
both target tumour response and patient beneﬁt were achieved; in
eight tumour response was achieved but not patient beneﬁt; and
in seven no target tumour response occurred but patient beneﬁt
was still achieved. Changes from baseline in FACT-H&N scores were
similar between the groups; FACT-H&N score was not related to
target tumour response, patient beneﬁt, or KPS (which was stable
during the blinded period in both study groups).
Drug exposure
During the blinded phase, CDDP/epi gel recipients had a median
of four (range one–six) treatments and placebo recipients received
a median of three (range one–six) treatments. Median dose per
target tumour treatment was 1.6 ml (range, 0.2–8.5) for active
gel and 1.7 ml (range, 0.5–10) for placebo, and median cumulative
dose was 5.4 ml (range, 1.0–46) and 5.3 ml (range, 0.8–29),
respectively. Over 80% of assigned dose was delivered in most
treatments; per cent dose delivery ranged from 41 to 213% for
active treatment and from 58 to 693% for placebo. Non-delivery
of the full assigned dose most commonly occurred because the
target tumour could not accommodate the entire dose, in 11%
(28 out of 250) of active gel treatments and 10% (11 out of
107) placebo gel treatments.
Safety
Adverse events during or 420 min after injection were mostly
injection site pain, in eight (14%) of CDDP/epi gel recipients
(severe in two, moderate in ﬁve) and one (3%) of the placebo reci-
pients. Mild to moderate tachycardia in three active gel recipients
may have been a reaction to either to pain or to epinephrine
released from the injection site.
Local cytotoxic effects (erosion, erythema, eschar, necrosis, swel-
ling, and ulceration) were more frequent and marked in the
CDDP/epi gel group than in placebo recipients (Table 3). The
development of these effects varied among patients, but generally
erythema, swelling, and ulceration were most severe after the ﬁrst
treatment; erosion, necrosis, and eschar were greater following
the second treatment; and the effects gradually resolved over the
following 2 to 5 months. Responding target tumours, as opposed
to non-responding target tumours, tended to develop more erosion
(47 vs 32%), necrosis (87 vs 47%), and eschar (33 vs 18%),
although these differences were not statistically signiﬁcant (border-
line signiﬁcance, CMH exact test P=0.055, was found for eschar).
Aside from local cytotoxic effects, the most common local adverse
event sustained beyond the immediate injection period was pain,
reported by eight (14%) in the active group (severe in two, moder-
ate in six) and three (9%) in the placebo group (severe in one,
moderate in two).
Systemic adverse events of pain, headache, nausea, vomiting,
and hypomagnesemia were slightly higher in CDDP/epi gel recipi-
ents than placebo recipients (Table 4). Forty-eight deaths occurred
after the start of treatment (26 active, 22 placebo), nearly all due to
progression or complications of cancer, and none were judged to
be related to treatment. Eight patients assigned to CDDP/epi gel
each reported one serious adverse event at least possibly related
to treatment: anaemia, allergic reaction, haemorrhage, pallor,
blindness, cardiac arrest (non-fatal), oedema, and swelling. Treat-
ment was discontinued following the ﬁrst ﬁve of these events.
The allergic reaction was severe, acute, and not related to the
collagen component of CDDP/epi gel (anticollagen IgG testing
was negative), but rather to another component (possibly cispla-
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Table 2 Rate of target tumour response during the blinded period
Number (%) Responses
Patients (n) CR PR CR+PR SD PD NER 95% CI (%) P value
Total
CDD/epi gel (57) 9 (16) 5 (9) 14 (25) 19 (33) 16 (28) 8 (14) 14–38
Placebo gel (35) 1 (3) 0 1 (3) 10 (29) 14 (40) 10 (29) 0.07–15 0.007
a
Stratum I
CDDP/epi gel (31) 6 (19) 4 (13) 10 (32) 10 (32) 7 (23) 4 (13) 17–51
Placebo (17) 1 (6) 0 1 (6) 5 (29) 6 (35) 5 (29) 0.15–29 0.07
b
Stratum II
CDDP/epi gel (26) 3 (12) 1 (4) 4 (15) 9 (35) 9 (35) 4 (15) 4.4–35
Placebo (18) 0 0 0 5 (28) 8 (44) 5 (28) 0–19 0.13
b
CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; NER: not evaluable for response.
aCMH exact test.
bFisher’s exact test.
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of the tongue from a major blood vessel following study drug over-
dose (5125% of assigned study drug volume without reﬂux) and
was managed by cauterization. The (hemifacial) pallor may have
been caused by vasospasm secondary to intra-arterial leakage of
study medication from the submandibular tumour. Sudden onset
of complete right-eye blindness following study drug overdose
was probably caused by an isolated right optic nerve lesion (the
patient recovered only light sensitivity). Changes in haematology
and chemistry values were infrequent and typical of those in
patients with advanced cancer. There was no evidence of the renal
toxicity or myelotoxicity typical of systemic cisplatin, except for
one occurrence of treatment-related anemia (moderate) and one
of mild leukopenia.
DISCUSSION
The results of therapy were assessed by evaluating both local
tumour response and patient beneﬁt, a validated measure of how
tumour response affected patient well-being. In these heavily pre-
treated patients with advanced head and neck squamous cell carci-
noma, during the blinded phase, the target tumour responded in
25% (14 out of 57) treated with CDDP/epi gel vs 3% (one out
of 35) treated with placebo (P=0.007). Nearly all responding target
tumours (86%) remained in local remission when patients left the
study, and the extent of response in patients with PR was notable:
median maximal tumour shrinkage of 94% (range, 60–99). The
rate of patient beneﬁt in the CDDP/epi gel group (19%) during
the blinded phase was more than twice that in the placebo gel
group (9%), but the difference was not statistically signiﬁcant.
Patient beneﬁt was positively and signiﬁcantly (P=0.024) associated
with target tumour response, supporting the hypothesis that regres-
sion of the most clinically dominant tumour can relieve or prevent
the patient’s most life-impacting symptom.
Target tumour response occurred after a median of 53 days and
4.5 treatments in the 14 actively treated patients who responded
during the blinded phase. Responses were durable, lasting a median
64 days, considering the advanced disease and limited expected
survival of the study population. Duration of response was a
conservative estimate, as local responses continued beyond the last
study observation point, but may have impacted patient well-being,
as reﬂected in the patient beneﬁt scores. Mean time to target
tumour progression was nearly three times as long in the CDDP/
epi gel group as in the placebo group (128 vs 44 days).
In this vulnerable study population, CDDP/epi gel had a toler-
able safety proﬁle, with adverse effects usually occurring at
predictable times (during and shortly after the injection procedure
and during the healing process) and involving predictable events
(commonly pain and cytotoxicity) generally limited to the tumour
site. As expected, the cytotoxic mode of action of CDDP/epi gel
resulted in more frequent and more severe cytotoxic events in
the active group, which peaked after the second or third treatment
and generally resolved during the next 2 to 5 months. Cytotoxic
events also occurred in the placebo group, albeit less frequently
and probably as a result of advancing cancer (Dvorak, 1986).
Systemic adverse effects were infrequent, and the nephrotoxicity,
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Table 4 Treatment-related adverse events reported in 45% of patients: blinded period (n=92)
a
Number (%) of Patients Reporting Event
CDDP/epi Gel (n=57) Placebo Gel (n=35)
Adverse Event Mild Moderate Severe Any
b Mild Moderate Severe Any
b
Immediate injection reactions
Pain 1 (2) 5 (9) 2 (4) 8 (14) 0 1 (3) 0 1 (3)
Tachycardia 2 (4) 1 (2) 0 3 (5) 0 0 0 0
Local reactions at the treatment site
Pain 0 6 (11) 2 (4) 8 (14) 0 2 (6) 1 (3) 3 (9)
Necrosis 1 (2) 3 (5) 0 4 (7) 0 0 0 0
Oedema, face 2 (4) 2 (4) 0 4 (7) 0 0 0 0
Dysphagia 1 (2) 1 (2) 1 (2) 3 (5) 1 (3) 0 1 (3) 2 (6)
Systemic/other reactions
Nausea 4 (7) 0 0 4 (7) 0 0 0 0
Vomiting 4 (7) 0 0 4 (7) 0 0 0 0
Pain 1 (2) 1 (2) 1 (2) 3 (5) 0 0 0 0
Hypomagnesemia 1 (2) 0 2 (4) 3 (5) 0 0 0 0
Headache 1 (2) 2 (4) 0 3 (5) 0 0 0 0
aThe 92 total patients include 1 who received no drug because of pain at the ﬁrst treatment visit.
bIncludes events for which severity was not reported.
Table 3 Local tissue conditions associated with treatment
a
CDDP/epi Gel (n=57) Placebo Gel (n=35)
Local Effect No. of Patients % No. of Patients %
Erosion
mild 7 12 5 14
moderate 11 19 2 6
severe 2 4 1 3
Erythema
mild 8 14 1 3
moderate 9 26 4 11
severe 2 4 0 0
Eschar
mild 4 7 2 6
moderate 6 11 0 0
severe 4 7 1 3
Necrosis
mild 12 21 1 3
moderate 14 25 3 9
severe 11 19 3 9
Swelling
mild 4 7 2 6
moderate 9 16 4 11
severe 2 4 0 0
Ulceration
mild 8 14 4 11
moderate 10 18 0 0
severe 4 7 1 3
aCytotoxic effects reﬂect changes of 1 point or more from baseline in severity based
on a 4-point scale of none, mild, moderate, or severe.
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cisplatin were absent except for treatment-related moderate anae-
mia and mild leukopenia in one patient each.
The most common adverse effect of treatment was local pain,
affecting up to 28% of patients. Although type of analgesia (narco-
tic vs non-narcotic) was not related to occurrence of moderate or
severe pain, speciﬁc patient characteristics (such as prior regional
pain status, general pain tolerance, limitations of comorbidity on
pain therapy, and treatment history) may have affected the physi-
cian’s choice of analgesia.
The next most frequent adverse events among CDDP/epi gel
recipients – necrosis (7%), facial oedema (7%), tachycardia
(5%), and dysphagia (5%) – were much less common than pain
and usually mild or moderate in severity. Nausea and vomiting
each were reported in 7% of active gel recipients, and may have
been related to pain medication or the pain of the procedure in
some cases. Local infection was relatively rare (three cases) and
was managed on an outpatient basis by parenteral or oral anti-
biotics.
The Treatment Goals Questionnaire and patient beneﬁt algo-
rithm demonstrated the clinical beneﬁt of CDDP/epi gel, as
indicated by the statistically signiﬁcant association between target
tumour response and patient beneﬁt. In 15 cases, the patient had
either target tumour response or patient beneﬁt but not both. In
four of these patients, stable disease or tumour regression of
550% (below the level required for tumour response) may have
been sufﬁcient to produce patient beneﬁt, and in one patient,
beneﬁt preceded documented tumour regression of 450%. In six
of the eight cases in which patients achieved target tumour
response but not patient beneﬁt, there was no clear evidence that
the goals chosen were unrealistic or could not have been reasonably
expected as a result of tumour response. In contrast to the Treat-
ment Goals Questionnaire, both the KPS and FACT-H&N were
relatively insensitive to the effect of local therapy.
The patients in this study, in which the most problematic
tumours were selectively treated, had substantial tumour response
rates to CDDP/epi gel even compared with patients with more
favourable prognoses (Huber et al, 1995), and these responses were
often accompanied by life-enhancing clinical beneﬁts. Two-thirds
of the responses (nine out of 14) were complete, a CR:PR ratio
of about 2:1, reversing the typical CR:PR ratio in studies of
systemic cisplatin therapy (generally about 1:4; Forastiere et al,
1992; Jacobs et al, 1992; Clavel et al, 1994). Therapy with
CDDP/epi gel can be administered on an out-patient basis, which
is especially important to patients whose remaining life expectancy
is limited and needed for family and personal affairs. Out-patient
treatment also can protect these frail patients from nosocomial
infection and other hospitalisation-associated hazards. The beneﬁts
of CDDP/epi gel treatment demonstrated in this study would be
difﬁcult to obtain from other treatments available to this patient
population, who might not tolerate or might be resistant to
systemic chemotherapy, might already have received maximal doses
of radiation, and would likely consider the morbidity of additional
surgery unacceptable.
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